JAK2(V617F) Mutation in Korean Patients with Essential Thrombocythemia.
10.3343/kjlm.2007.27.2.77
- Author:
Jeong Yeal AHN
1
;
Soo Jin YOO
;
Soo Mee BANG
;
Pil Whan PARK
;
Yiel Hea SEO
;
Dong Bok SHIN
;
Jae Hoon LEE
Author Information
1. Department of Laboratory Medicine, Gil Medical Center, Gachon University, Incheon, Korea.
- Publication Type:Original Article ; English Abstract
- Keywords:
JAK2 mutation;
Essential thrombocythemia;
Reactive thrombocytosis
- MeSH:
Aged;
Alleles;
Amino Acid Substitution;
Blood Platelets/metabolism;
Female;
Humans;
Janus Kinase 2/*genetics;
Korea;
Male;
Middle Aged;
Polymerase Chain Reaction;
Thrombocytosis/blood/*diagnosis/genetics
- From:The Korean Journal of Laboratory Medicine
2007;27(2):77-82
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Essential thrombocythemia (ET) is thought to reflect transformation of a multipotent hematopoietic stem cell, but its molecular pathogenesis remains obscure. But tyrosine kinase, especially Janus kinase 2 (JAK2), has been implicated in myeloproliferative disorders other than chronic myeloid leukemia. We investigated the frequency of JAK2 mutation and its correlation with other clinicopathologic variables in Korean patients with ET and reactive thrombocytosis (RT). METHODS: JAK2 mutation analysis was performed on genomic DNA from bone marrow aspirates of 24 patients with ET and peripheral blood in 36 patients with RT using allele-specific PCR. RESULTS: JAK2 mutation was detected in 11 patients (46%) among the 24 patients with ET and was not found in 36 patients with RT. In patients with ET, older age and leukocytosis were related with JAK2 mutation without statistical significance (P=0.172 and 0.094, respectively). But this mutation was not correlated with sex, hemoglobin, platelet count, splenomegaly, increased cellularity of bone marrow, bone marrow fibrosis and vascular complications. CONCLUSIONS: The current observation strengthens the specific association between JAK2 mutation and ET. At the diagnosis of ET in Korean patients, identification of JAK2 mutation should be incorporated in the basis for new approaches.
